Keywords: داساتینیب; Dasatinib; Deep molecular response; Imatinib; Minimal residual disease; Nilotinib;
مقالات ISI داساتینیب (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: داساتینیب; Transfusion; Allergic reaction; Basophil activation test; Allergen; Dasatinib;
Keywords: داساتینیب; CDK; cyclin-dependent kinase; CKD; chronic kidney disease; DR; dietary restriction; ESRD; end stage renal disease; FOXO4; Forkhead BOX O 4; HSP-90; heat shock protein 90; IF; interstitial fibrosis; IL-6; interleukin-6; IRI; ischemia reperfusion injury; NS
Keywords: داساتینیب; Glucosylated polymeric nanomicelles; Glucose-avid pediatric sarcomas; Rhabdomyosarcoma; Tumor targeting; Dasatinib; Patient-derived xenografts;
Keywords: داساتینیب; Phosphoproteomics; Kinase inhibitors; Drug resistance; Pazopanib; Dasatinib; Cell signalling;
Keywords: داساتینیب; Allogeneic stem cell transplantation; BCR-ABL; chronic myeloid leukaemia; dasatinib; imatinib; nilotinib; Philadelphia chromosome; ponatinib; quantitative RT-PCR; tyrosine kinase inhibitors;
Keywords: داساتینیب; Senolytics; SASP inhibitors; Dasatinib; Quercetin; Navitoclax; Fisetin; A1331852; A1155463; Senescent Cell Anti-apoptotic Pathways (SCAPs);
Keywords: داساتینیب; Acute lymphoblastic leukemia; Philadelphia chromosome; Tyrosine kinase inhibitor; Imatinib; Dasatinib; Ponatinib;
Keywords: داساتینیب; Acute lymphoblastic leukemia; ALL; Allogeneic; Cytogenetics; Dasatinib; Imatinib; Minimal residual disease; MRD; Nilotinib; Philadelphia chromosome positive; Ph+; Ponatinib; Stem cell transplant; TKI; Tyrosine kinase inhibitor;
Keywords: داساتینیب; przewlekła białaczka szpikowa; oporność na imatynib; dazatynib; nilotynibChronic myeloid leukemia; Imatinib resistance; Nilotinib; Dasatinib
Keywords: داساتینیب; Bone marrow; Bone metabolism; Dasatinib; Digital image analysis; Trabecular bone
Keywords: داساتینیب; Bosutinib; Dasatinib; Nilotinib; Ponatinib; Radotinib
Keywords: داساتینیب; CML; Dasatinib; Liver dysfunction; Nilotinib; Renal dysfunction;
Keywords: داساتینیب; Cure; Dasatinib; Imatinib; Molecular remission; Nilotinib;
Keywords: داساتینیب; Adherence; Dasatinib; Frequency of response assessments; Imatinib; Nilotinib;
Keywords: داساتینیب; Adverse events; Allogeneic stem cell transplantation; Dasatinib; Large granular lymphocyte; Philadelphia-positive ALL
Keywords: داساتینیب; adverse sequelae; alopecia; antiangiogenic agents; anticancer; BCR-ABL; bevacizumab; cancer treatment; canertinib; cetuximab; chemotherapy; cutaneous adverse effects; dasatinib; dermatologic toxicities; disturbed wound healing; drug eruption; drug rash; d
Keywords: داساتینیب; CLL; Fludarabine refractory; Microenvironment; Kinase inhibitor; Dasatinib; NOXA;
Keywords: داساتینیب; Chronic myeloid leukemia; Tyrosine kinase inhibitors; Imatinib; Dasatinib; Nilotinib; Bosutinib; Ponatinib;
Keywords: داساتینیب; Custirsen; Dasatinib; Docetaxel; Prostate cancer; Review; Targeted therapy
Keywords: داساتینیب; chronic myeloid leukemia; cost-utility analysis; dasatinib; imatinib; leukemia; nilotinib; Thailand;
Keywords: داساتینیب; Chronic myeloid leukemia; Imatinib; Nilotinib; Dasatinib; Drug resistance; Adverse drug event;
Keywords: داساتینیب; chronic myeloid leukemia; complete cytogenetic response; dasatinib; health technology assessment; HTA; imatinib; intermediate outcomes; major molecular response; nilotinib; surrogate end points; systematic review; technology appraisal;
Keywords: داساتینیب; Dasatinib; Imatinib; Nilotinib; Optic neuropathy; Chronic myeloid leukemia; Visual campimetry/perimetry
Simultaneous determination of doxorubicin and dasatinib as two breast anticancer drugs uses an amplified sensor with ionic liquid and ZnO nanoparticle
Keywords: داساتینیب; Doxorubicin; Dasatinib; ZnO nanoparticle; 1-butyl-3-methylimidazolium tetrafluoroborate;
Vogt-Koyanagi-Harada disease like presentation in patients with chronic myeloid leukemia
Keywords: داساتینیب; Chronic myeloid leukemia; Panuveitis; Vogt-Koyanagi-Harada disease; Tyrosine kinase inhibitors; Dasatinib; Imatinib;
BCL2 inhibitor ABT-199 and JNK inhibitor SP600125 exhibit synergistic cytotoxicity against imatinib-resistant Ph+ ALL cells
Keywords: داساتینیب; ABL; Abelson kinase; ALL; acute lymphoblastic leukemia; BCR; break clustering region; CML; chronic myeloid leukemia; DST; dasatinib; IMT; imatinib; NRT; nirotinib; Ph+; Philadelphia chromosome positive; TKI; tyrosine kinase inhibitor; Ph+ ALL; Imatinib-re
Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study
Keywords: داساتینیب; Chronic myeloid leukemia; Regulatory T cell; Natural killer cell; Dasatinib;
Enhanced perforin expression associated with dasatinib therapy in natural killer cells
Keywords: داساتینیب; Dasatinib; JAK; STAT; Perforin; Interferon-γ; IL-2;
Dasatinib sensitises KRAS-mutant cancer cells to mitogen-activated protein kinase kinase inhibitor via inhibition of TAZ activity
Keywords: داساتینیب; Dasatinib; Trametinib; KRAS; TAZ;
Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma
Keywords: داساتینیب; Mesothelioma; Dasatinib; Src kinase; Platelet-derived growth factor receptor;
Phase II Study of Paclitaxel and Dasatinib in Metastatic Breast Cancer
Keywords: داساتینیب; Advanced breast cancer; Dasatinib; Metastatic breast cancer; Paclitaxel; SRC;
High-mobility group box 1 protein-mediated necroptosis contributes to dasatinib-induced cardiotoxicity
Keywords: داساتینیب; HMGB1; high mobility group box 1; CML; chronic myelogenous leukemia; Ph+ALL; Philadelphia chromosome positive acute lymphoblastic leukemia; RIP1; receptor-interacting protein kinase 1; RIP3; receptor-interacting protein kinase 3; MLKL; mixed lineage kinas
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq
Keywords: داساتینیب; Atypical CML; CSF3R; SPTAN1; fusion; dasatinib;
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells
Keywords: داساتینیب; Epithelial-mesenchymal transition; Acquired resistance; Dasatinib; Third- generation EGFR-TKI; Non-small cell lung cancer;
How is the Ph-like signature being incorporated into ALL therapy?
Keywords: داساتینیب; Acute lymphoblastic leukemia; Philadelphia chromosome-like; tyrosine kinase inhibitor; Janus kinase inhibitor; Imatinib; Dasatinib; Ruxolitinib;
IL6 is associated with response to dasatinib and cetuximab: Phase II clinical trial with mechanistic correlatives in cetuximab-resistant head and neck cancer
Keywords: داساتینیب; EGFR; epidermal growth factor receptor; SFK; Src-family kinase; HNSCC; head and neck squamous cell carcinoma; IL6; interleukin-6; HGF; hepatocyte growth factor; VEGF; vascular endothelial growth factor; IRB; institutional review board; PD; progressive dis
Research paperA new mechanism of resistance to ABL1 tyrosine kinase inhibitors in a BCR-ABL1-positive cell line
Keywords: داساتینیب; Chronic myeloid leukemia; Resistance; SRC kinase; FYN; MEK/ERK; Dasatinib;
How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Keywords: داساتینیب; Philadelphia-positive; Ph+, Ph-positive; Acute lymphoblastic leukemia; Older; Elderly; Adult; Imatinib; Dasatinib; Hematopoietic cell transplantation;
Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy
Keywords: داساتینیب; Dasatinib; Prodrug micelles; Redox responsive; Doxorubicin; Co-delivery;
A validated UPLC-MS/MS method for simultaneous determination of imatinib, dasatinib and nilotinib in human plasma
Keywords: داساتینیب; UPLC-MS/MS; Imatinib; Dasatinib; Nilotinib; Polymorphism;
Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC)
Keywords: داساتینیب; Acalabrutinib; Alectinib; Brigatinib; Ceritinib; Crizotinib; Dabrafenib; Dasatinib; Erlotinib; Gefitinib; Ibrutinib; Imatinib; Lorlatinib; Nilotinib; Osimertinib; Rociletinib; Trametinib; Vemurafenib;
Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Keywords: داساتینیب; Dasatinib; Colitis; Allogeneic; Hematopoietic cell transplantation; Hemorrhagic;
Optimizing the Use of TKIs in the Management of Chronic Myelogenous Leukemia
Keywords: داساتینیب; Bosutinib; Chronic myelogenous leukemia; Dasatinib; Imatinib; Nilotinib; Tyrosine kinase inhibitor
Dasatinib first-line: Multicentric Italian experience outside clinical trials
Keywords: داساتینیب; Chronic myeloid leukemia; Dasatinib; Prognosis
Risk-Adapted Approach to HLA-Matched Sibling Hematopoietic Cell Allografting: Impact of Adjusting Conditioning Intensity and Integrating Post-Transplant Therapeutic Interventions
Keywords: داساتینیب; 5-Azacytidine; Allogeneic stem cell transplantation; Dasatinib; Personalized conditioning; Sorafenib;
Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods
Keywords: داساتینیب; Imatinib; Nilotinib; Dasatinib; HPLC; LC-MS/MS;
Micellar delivery of dasatinib for the inhibition of pathologic cellular processes of the retinal pigment epithelium
Keywords: داساتینیب; Dasatinib; Polymeric micelles; Nanoparticles; Proliferative vitreoretinopathy; Retinal pigment epithelium
Dasatinib promotes paclitaxel-induced necroptosis in lung adenocarcinoma with phosphorylated caspase-8 by c-Src
Keywords: داساتینیب; Paclitaxel; Dasatinib; Necroptosis; Lung adenocarcinoma
Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity ★
Keywords: داساتینیب; Urothelial carcinoma; Bladder; Neoadjuvant therapy; Protein kinase inhibitors; Src-family kinases; Dasatinib; Translational medical research